IMIPRO-500 (Imipenem 500Mg + Cilastatin 500Mg)

Composition:

Imipenem 500 mg and Cilastatin 500 mg per vial

Description:

IMIPRO-500 is a combination of Imipenem, a broad-spectrum carbapenem antibiotic, and Cilastatin, a renal dehydropeptidase inhibitor that prevents the enzymatic degradation of Imipenem in the kidney. The combination provides potent bactericidal activity against a wide range of Gram-positive, Gram-negative and anaerobic organisms and is indicated for the treatment of severe or complicated infections such as intra-abdominal infections, complicated urinary tract infections, skin and soft tissue infections, sepsis, and nosocomial pneumonias where multidrug-resistant pathogens are suspected.

Precautions:

IMIPRO-500 should be prescribed and administered under medical supervision. Exercise caution in patients with a history of hypersensitivity to beta-lactam antibiotics. Dose adjustment is required in patients with renal impairment; renal function should be assessed prior to and during therapy. Use cautiously in patients with a history of seizure disorders or central nervous system disorders as Imipenem may lower the seizure threshold. Concomitant use with valproic acid or divalproex may reduce anticonvulsant levels and increase the risk of seizures; alternative anticonvulsant therapy should be considered. Use during pregnancy or breastfeeding only if clearly needed and prescribed by a physician. Inform the prescriber of all concomitant medications to avoid interactions.

Adverse Effects:

Common adverse effects may include nausea, vomiting, diarrhea, injection site reactions and rash. Neurological adverse events such as headache, dizziness or, rarely, seizures may occur, particularly in patients with renal impairment or prior seizure history. Hypersensitivity reactions ranging from mild rash to severe anaphylaxis have been reported. Hematologic disturbances (e.g., eosinophilia, neutropenia), liver enzyme elevations and Clostridium difficile–associated diarrhea are possible with antibiotic use.

Storage:

Store the vial below 25°C, protected from light and moisture. The product is typically supplied as a sterile dry powder for injection; reconstitute and dilute according to the prescribing information immediately before use. Use reconstituted or diluted solutions within the time period recommended by the manufacturer and discard any unused portion. Keep out of reach of children and do not use after the expiry date.